JP Morgan Chase’s Global Blood Therapeutics, Inc. GBT Stock Holding History

JP Morgan Chase’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-170,000	Closed	-$9.18M	–	6051
2019 Q2	$9.18M	Buy	+170,000	New	+$9.77M	﹤0.01%	2172
2019 Q1	–	Sell	-279,600	Closed	-$11.5M	–	6133
2018 Q4	$11.5M	Buy	279,600 +129,700	+87%	+$4.86M	﹤0.01%	1902
2018 Q3	$5.7M	Buy	149,900 +129,800	+646%	+$5.75M	﹤0.01%	2638
2018 Q2	$909K	Buy	+20,100	New	+$915K	﹤0.01%	3878
2017 Q4	–	Sell	-70,000	Closed	-$2.06M	–	5638
2017 Q3	$2.06M	Buy	+70,000	New	+$1.97M	﹤0.01%	3134

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's GBT Position: Q4 2022 in Review

JP Morgan Chase sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 2,304,636 shares — an estimated $157M sold.

JP Morgan Chase first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $157M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

JP Morgan Chase reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
JP Morgan Chase sold 2,304,636 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $157M.
JP Morgan Chase first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
JP Morgan Chase's Global Blood Therapeutics, Inc. position peaked at $157M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.